Evidence map›Paper›PMID 38854390›Full record

ArticleOpen forum infectious diseases2024

Multisite Study of the Management of Musculoskeletal Infection After Trauma: The MMUSKIT Study.

Jessica Seidelman, Alaina S Ritter, Emily Poehlein, Cynthia L Green, Damon V Briggs, Tristan Chari, Aaron D Therien, Alexandra Hunter Aitchison, Kiera Lunn, Christian F Zirbes and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jessica SeidelmanDivision of Infectious Diseases and International Health, Department of Medicine, School of Medicine, Duke University, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0001-7117-513X
Alaina S RitterDivision of Infectious Diseases and Global Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Emily PoehleinDepartment of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, North Carolina, USA.
Cynthia L GreenDepartment of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, North Carolina, USA.
Damon V BriggsSchool of Medicine, Duke University, Durham, North Carolina, USA.
Tristan ChariSchool of Medicine, Duke University, Durham, North Carolina, USA.
Aaron D TherienSchool of Medicine, Duke University, Durham, North Carolina, USA.
Alexandra Hunter AitchisonSchool of Medicine, Duke University, Durham, North Carolina, USA.
Kiera LunnSchool of Medicine, Duke University, Durham, North Carolina, USA.
Christian F ZirbesSchool of Medicine, Duke University, Durham, North Carolina, USA.
Tanvi ManoharDivision of Infectious Diseases and Global Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Diana V RijoDepartment of Orthopedics and Sports Medicine, University of Florida, Gainesville, Florida, USA.
Jennifer E HagenDepartment of Orthopedics and Sports Medicine, University of Florida, Gainesville, Florida, USA.
Michael T TalericoDepartment of Orthopedics and Sports Medicine, University of Florida, Gainesville, Florida, USA.
Malcolm R DeBaunDepartment of Orthopaedic Surgery, School of Medicine, Duke University, Durham, North Carolina, USA.
Christian A PeanDepartment of Orthopaedic Surgery, School of Medicine, Duke University, Durham, North Carolina, USA.
Laura CertainDivision of Infectious Diseases, University of Utah, Salt Lake City, Utah, USA.
Sandra B NelsonDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

Support for QA/QC for Prior Approval ProcessUL1TR002553 · NCATS · DUKE UNIVERSITY · PI LI, JENNIFER S, MCNAMARA, JAMES O. · 2018 to 2023
$58.5M
NCATS NIH HHS UL1 TR002553
6 · The paper itself

Abstract

Background: The optimal duration and choice of antibiotic for fracture-related infection (FRI) is not well defined. This study aimed to determine whether antibiotic duration (≤6 vs >6 weeks) is associated with infection- and surgery-free survival. The secondary aim was to ascertain risk factors associated with surgery- and infection-free survival. Methods: We performed a multicenter retrospective study of patients diagnosed with FRI between 2013 and 2022. The association between antibiotic duration and surgery- and infection-free survival was assessed by Cox proportional hazard models. Models were weighted by the inverse of the propensity score, calculated with a priori variables of hardware removal; infection due to Results: Of 96 patients, 54 (56.3%) received ≤6 weeks of antibiotics and 42 (43.7%) received >6 weeks. There was no association between longer antibiotic duration and surgery-free survival (hazard ratio [HR], 0.95; 95% CI, .65-1.38; Conclusions: The ideal duration of antibiotics to treat FRI is unclear. In this multicenter study, there was no association between antibiotic treatment duration and surgery- or infection-free survival.

Indexed as

fracture-related infectioninfection after fracture fixation

Identifiers

PMID38854390
PMCPMC11161894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.